Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 98,392 shares of the biotechnology company’s stock after selling 6,826 shares during the quarter. Bank of New York Mellon Corp owned 0.16% of Ascendis Pharma A/S worth $13,546,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at about $30,000. Blue Trust Inc. raised its stake in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 328 shares during the period. GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the period. Sanctuary Advisors LLC acquired a new stake in Ascendis Pharma A/S during the 4th quarter valued at $203,000. Finally, Legato Capital Management LLC grew its holdings in Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 134 shares in the last quarter.

Analyst Upgrades and Downgrades

ASND has been the subject of a number of analyst reports. Stifel Nicolaus upped their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Wedbush reissued an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. TD Cowen lowered their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group boosted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $202.36.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $150.31 on Thursday. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $158.00. The stock has a fifty day moving average price of $137.77 and a 200 day moving average price of $134.52. The company has a market cap of $9.12 billion, a P/E ratio of -21.17 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. As a group, research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.